source
- GSK goes to China for $1B siRNA deal in Arrowhead's obesity laneGSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup. The UK pharma is teaming with Suzho…Endpoints · 2mo ago↗ source
- Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma ManagementAjai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.onclive · 2mo ago↗ source
- Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment DurationNew SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.onclive